Background: Evidence indicates not only carcinogenic effect of cigarette smoking but also its immunosuppressive effect. We hypothesized that the association of smoking with colorectal cancer risk might be stronger for tumors with lower anti-tumor adaptive immune response. Methods: During follow-up of 134 981 participants (3 490 851 person-years) in the Nurses' Health Study and Health Professionals Follow-up Study, we documented 729 rectal and colon cancer cases with available data on T-cell densities in tumor microenvironment. Using the duplication-method Cox regression model, we examined a differential association of smoking status with risk of colorectal carcinoma subclassified by densities of CD3 þ cells, CD8 þ cells, CD45RO (PTPRC) þ cells, or
colorectal cancer risk may be stronger for tumors characterized by high-degree CpG island methylator phenotype (CIMP), and high-level microsatellite instability (MSI) due to epigenetic silencing of MLH1 gene (10) (11) (12) (13) . These findings provide evidence that smoking may induce epigenetic changes that can drive colorectal carcinogenesis (14, 15) .
The pivotal role of the host immunity in regulating neoplastic progression is gaining greater attention (16) (17) (18) (19) (20) (21) . MSIhigh colorectal cancer with numerous frameshift mutations may produce abundant immunogenic peptides that can elicit intense immune response in the tumor microenvironment (22) (23) (24) . One important component of immune response to tumor is lymphocytic infiltrate, which has been associated with prolonged patient survival in colorectal cancer (25) (26) (27) (28) (29) . Accumulating evidence indicates that smoking can not only provoke systemic inflammation but also impair adaptive and innate immunity (30, 31) . In addition, experimental data suggest that smoking may suppress T cell-mediated tumor-specific immunity, potentially promoting tumor evolution (31) (32) (33) . We therefore hypothesized that the association of smoking with colorectal cancer risk might be stronger for carcinomas with lower T cell density than for carcinomas with higher T cell density.
To test our hypothesis, we conducted a molecular pathological epidemiology study using integrated data on lifestyle factors, colorectal cancer incidence, and pathological immune response to tumor within two large prospective cohort studies. We examined differential associations of smoking with colorectal cancer risk according to densities of tumorinfiltrating T cells. The T cell co-receptor CD3 helps to activate effector function of T cells, and we evaluated CD3 expression as a marker of pan-T cells. We also evaluated specific T cell markers including CD8 for cytotoxic T cells, CD45RO (an isoform of the PTPRC protein) for memory T cells, and FOXP3 for regulatory T cells; the densities of these cells have been associated with high-level MSI and patient prognosis in colorectal cancer (20, 26) .
Methods

Study Population
We utilized two prospective cohort studies in the United States: the Nurses' Health Study (NHS, 1 21 701 women aged 30-55 years followed since 1976) and the Health Professionals Follow-up Study (HPFS, 51 529 men aged 40-75 years followed since 1986) ( Table 1) (34) . Participants have been sent questionnaires to report lifestyle factors, including smoking behavior and newly diagnosed diseases, every two years and to report dietary patterns every four years. At baseline, we excluded participants who did not report smoking status, did not return the initial food frequency questionnaire (in 1980 for the NHS and 1986 for the HPFS), left a large number of items blank (>10 of 61 items for the NHS and >70 of 131 items for the HPFS), or reported unreasonable food intakes (<600 or >3500 calories/day for women, and <800 or >4200 calories/day for men). We also excluded participants with a history of inflammatory bowel disease or cancer (except for nonmelanoma skin cancer). Participants were followed until diagnosis of colorectal cancer, death, or the end of follow-up (January 31, 2012 for the HPFS and June 1, 2012 for the NHS), whichever came first. The followup rate was more than 90% for each follow-up questionnaire in both cohorts.
Informed consent was obtained from all participants at enrollment. This study was approved by the institutional review boards at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital (Boston, MA).
Assessment of Smoking Behavior
Detailed information on smoking behavior was collected as reported previously (12, 35) . Current smoking status and daily cigarette consumption for smokers have been reported by participants on biennial questionnaires since 1980 (the NHS) and 1986 (the HPFS). On the baseline questionnaires (1976 in the NHS and 1986 in the HPFS), participants were asked to report the age at which they began and ceased smoking (if applicable), as well as the average daily consumption of cigarettes. We calculated the duration of smoking cessation and cumulative pack-years of smoking (average daily consumption of cigarette packs x the number of years smoked).
Ascertainment of Colorectal Cancer Cases
In both cohorts, colorectal cancer cases were identified based on biennial questionnaires. For nonrespondents with colorectal cancer, colorectal cancer cases and deaths were ascertained using various information sources, including family members, US Postal Service authorities, and the National Death Index. We included both colon and rectal carcinomas, based on the colorectal continuum model (36, 37) . Study physicians, blinded to exposure data, reviewed medical records of identified colorectal cancer cases to confirm the diagnosis and record tumor characteristics. We collected formalin-fixed, paraffin-embedded tissue blocks of surgically resected tumors from hospitals throughout the US. Demographic or clinical data did not differ substantially by availability of tumor tissue (Supplementary Table 1 , available online) (38) .
Analyses of Tumor Pathological, Immune, and Molecular Features
A single pathologist (SO), blinded to other data, reviewed hematoxylin and eosin-stained tissue sections, confirmed diagnosis of colorectal carcinoma, and recorded pathological features including four components of lymphocytic reaction (tumor-infiltrating lymphocytes, intratumoral periglandular reaction, peritumoral lymphocytic reaction, and Crohn's-like lymphoid reaction) (25) . Each component was scored as negative/low, intermediate, or high. We constructed tissue microarrays for colorectal cancer cases with sufficient tissue materials, which included up to four cores from each case considering intratumor heterogeneity (39) . We used the data on tumor-infiltrating T cells from our previous study (26 (Figure 1 ). We marked neoplastic epithelial areas to exclude nonneoplastic areas (eg, stroma, normal mucosa, and necrotic regions). We averaged the densities of each T cell subset within a patient and dichotomized the density by the median value of the total colorectal cancer population. DNA was extracted from archival formalin-fixed, paraffin-embedded tumor tissue blocks. Tumor status of MSI, CIMP, and BRAF mutation was determined as previously described (40, 41) .
Statistical Analysis
All statistical analyses were performed using SAS software (version 9.4, SAS Institute, Cary, NC), and all P values were twosided. Our primary hypothesis testing was set to assess the heterogeneity between associations of smoking status (never, former, or current) with the risk of colorectal cancer subclassified by T cell densities (low vs high). We assessed the four T cell
and adjusted the a level to 0.01 ( 0.05/4) based on Bonferroni correction. All other assessments including evaluation of individual hazard ratio (HR) estimates represented secondary analyses, and we used the adjusted a level of 0.01. We used the Cox proportional hazards regression model to estimate HR of colorectal cancer incidence and the corresponding 95% confidence interval (CI). To assess the differential association of smoking status with incidence of colorectal cancer subclassified by T cell densities, we utilized the Table 1 . Age-standardized characteristics of participants according to smoking status in the Nurses' Health Study (NHS, 1980 (NHS, -2012 duplication-method Cox regression model for competing risks (42) . In analyses of a specific subtype of colorectal cancer, occurrence of other subtypes was treated as competing risk events. Using a likelihood ratio test, we examined the heterogeneity of subtype-specific associations and presented the statistical significance as a P value for heterogeneity (P heterogeneity ) (43) . In the multivariable Cox model, we initially included the covariates described in Table 2 and conducted a backward elimination with a threshold P of .05 to select variables for the final model. Cases with missing data (<6.1% for all covariates) were assigned to the majority category or the median value of a given covariate to limit the degrees of freedom of the models. For cases with missing data on menopause status/menopausal hormone therapy (11.0%), we assigned a separate indicator variable. The models were stratified by sex (only for pooled analyses), age, and calendar year of questionnaire cycle. Colorectal cancer cases without available data on T cell density and participants who died without diagnosis of colorectal cancer were treated as censored cases at the time of cancer diagnosis and death, respectively. We treated all variables as time dependent to account for changes over time. To reduce intra-individual variation and consider long-term influences, we used the cumulative average for relevant variables, which was the mean of all available data prior to each questionnaire cycle. When the assumption of proportionality of hazards was verified by assessing a time-varying covariate (ie, the cross-product of smoking status and follow-up time), we observed evidence on violation of this assumption. However, the Schoenfeld residual plots supported the proportionality of hazards during most of the follow-up period (data not shown), and thus, we used the Cox regression model. To examine the association of smoking status with colorectal cancer risk by T cell density adjusted for tumor MSI, CIMP, or BRAF mutation status, we conducted meta-regression analyses for multiple tumor subtyping markers (44) . We conducted tests of heterogeneity using the Q statistic and observed no statistically significant heterogeneity between the two cohorts (P heterogeneity > .13) for the association of smoking status with colorectal cancer subclassified by T cell densities. We therefore combined the cohorts for further analyses to increase statistical power. (Table 3, and Supplementary  Table 5 , available online, respectively). Cumulative pack-years smoked were associated with a higher risk of CD3 þ cell-low colorectal cancer (P trend < .001), but not with the risk of CD3 þ cellhigh cancer (P trend ¼ .68). Smoking status was associated with the amount of alcohol consumption, which might influence the host immune system (45) . However, we did not find a differential association of the amount of alcohol consumption with colorectal cancer risk by the density of T cells (data not shown).
Results
The association of smoking with the risk of CD3 þ cell-low colorectal cancer appeared to be stronger than that with the risk of CD3 þ cell-high cancer, regardless of tumor MSI, CIMP, or BRAF mutation status (Table 4 ), but statistical power was limited. In meta-regression analyses (44), a stronger association of smoking with CD3 þ cell-low colorectal cancer compared with that with CD3 þ cell-high cancer appeared to be consistent after adjustment for tumor MSI, CIMP, or BRAF mutation status (Table 5) . When we examined a differential association of smoking status with incidence of colorectal cancer subclassified by level of lymphocytic reaction, the association of smoking status with colorectal cancer risk appeared to be stronger for tumors with higher-level Crohn's-like lymphoid reaction than for tumors with lower-level reaction (Supplementary Table 6 , available online). However, this differential association was not observed after adjustment for tumor MSI status (Supplementary Table 7 , available online).
Discussion
In this large prospective study with up to 30 years of follow-up, we found a stronger association of smoking with colorectal carcinomas with lower T cell density than with higher T cell density. This differential association appeared consistent regardless of tumor status of MSI, CIMP, or BRAF mutation. Our current study suggests that the carcinogenic effects of smoking may be, at least in part, mediated through local suppression of T cell-mediated immune response to colorectal tumor.
The promising results of trials of immune checkpoint inhibitors that target the PDCD1 (programmed cell death 1, PD-1) or CD274 (PDCD1 ligand 1, PD-L1) protein have cast light on the modulation of T cell activity in the tumor microenvironment as a potential strategy for cancer treatment (46) (47) (48) pathway, but also compromise anti-tumor immunosurveillance through suppression of NK cells and dendritic cells (32, 59, 60) . Experimental data also indicate that exposure to cigarette smoke extract directly impairs T cell function via a reduction in cell proliferation and induction of cellular apoptosis (30, 61) and specifically affects levels of cytotoxic, regulatory, and helper T cells as well as B cells (31) . Furthermore, human population data also point to the immunosuppressive effects associated with smoking, including an increase in circulating regulatory T cells and a reduction in a wide spectrum of immune markers (62, 63) . Taking these facts into account, long-term exposure to smoking may induce immunosuppressive conditions in the tumor microenvironment, thereby assisting the evasion of immune mechanisms by tumor cells. Our study supports the possibility that smoking may impair the T cell-mediated *P trend was calculated using a two-sided linear tend test and the median value of each category of cumulative pack-years of smoking (continuous). CI ¼ confidence interval; HR ¼ hazard ratio. †Pheterogeneity was calculated using a two-sided likelihood ratio test for the heterogeneity between subtype-specific multivariable association measures. ‡Adjusted for the same set of covariates as Table 2 . The Cox models were stratified by age, calendar year of questionnaire cycle, and sex/cohort. Table 4 . Evidence indicates that smoking may increase the risk of MSI-high colorectal cancer, which is characterized by an intense immune response to the tumor (10) (11) (12) (13) (22) (23) (24) 47 ). This could explain our findings of a higher risk of colorectal cancer characterized by high-level Crohn's-like lymphoid reaction associated with current smoking before adjustment for tumor MSI status. This differential association was no longer observed after adjustment for tumor MSI status. In contrast, our study found a seemingly counterintuitive association of smoking with an increased risk of CD3 þ cell-low cancer. However, our findings may suggest the following explanation. Without the immunosuppressive effects of smoking, a fraction of MSI-high tumors may be eliminated by the intense immune response characteristic of MSI-high tumors. Smoking may suppress this immune response, which leads to an increased risk of MSI-high cancers in smokers. Therefore, our findings of the stronger association of smoking with CD3 þ cell-low colorectal cancer provide evidence for the mediation of the carcinogenic activity of smoking through impairment of T cell-mediated anti-tumor immunity. The current study has notable strengths. Owing to the biennial collection of data on lifestyle factors for more than 30 years of follow-up, we could evaluate the long-term effect of smoking on colorectal carcinogenesis without substantial recall bias while adjusting for potential confounders. Furthermore, we utilized the molecular pathological epidemiology approach to integrate data on lifestyle factors, cancer incidence, and tumor molecular and immune characteristics (51, 54) . The current study was based on the assessment of local T cell infiltrates in the colorectal cancer tissue rather than plasma immune biomarkers (62), thereby providing insights into the complex interactions between exposures, host factors, and neoplastic cells in the microenvironment.
ARTICLE
The current study has limitations. First, there was the possibility of unmeasured confounding. Second, we could not obtain tumor tissue samples from all colorectal cancer cases. However, demographic or clinical characteristics did not differ substantially between colorectal cancer patients with and without tumor tissue data (38) . Third, we evaluated up to four tumor cores in a tissue microarray for ease case considering the intra-tumor heterogeneity of T cell distributions, but this approach might still lead to a bias because of sampling of the cores. Nonetheless, this misclassification would most likely skew our findings toward the null association. Finally, our study was based on selected populations; most participants were non-Hispanic health professionals. Hence, our findings need to be validated in independent populations.
In conclusion, we have shown that the association of the risk of colorectal cancer with smoking is more pronounced for carcinoma subtype with lower quantities of CD3 þ cells than subtype with greater amounts of CD3 þ cells. Our study highlights the potential role of suppression of T cell-mediated antitumor immunity in mediating the effect of smoking on colorectal carcinogenesis.
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